The National Institute for Health and Clinical Excellence will face a judicial review into its decision to restrict access on the NHS to three dementia drugs at the High Court from 25 June.
The healthcare advisory body had ruled that three drugs, Aricept, Exelon and Reminyl, should no longer be available for people with mild or severe dementia, but drugs companies Eisai and Pfizer successfully persuaded the court to grant a review, the first into a Nice decision.
The hearing has been scheduled for four days.
Previous articles:
Alzheimer’s Society takes drugs storm to High Court
New guidance out as drug ruling bites
Alzheimer’s drug appeal rejected
A trauma-informed approach to social work: practice tips 
Problem gambling: how to recognise the warning signs 
Find out how to develop your emotional resilience with our free downloadable guide 
Develop your social work career with Community Care’s Careers and Training Guide 
‘Dear Sajid Javid: please end the inappropriate detention of autistic people and those with learning disabilities’
Ofsted calls for power to scrutinise children’s home groups
Seven in eight commissioners paying below ‘minimum rate for home care’
Facebook
X
LinkedIn
Instagram
Comments are closed.